Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study

References

• Ginsburg J, Hardiman P, Okolo S. Hormone replacement therapy in general practice. Br Med J 1991; 302: 1601–2
   Google Scholar
• Petitti DB, Perlman JR, Sidney S. Non-contraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289–93
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willet WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105–10
   PubMed Web of Science ®Google Scholar
• Bush TL, Barret-Connor E, Cowrn LD, et al. Cardiovascular mortality and non contraceptive use of estrogen in women: results from the lipid research clinics programme follow-up study. Circulation 1987; 75: 1102–9
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. Br Med J 1988; 297: 519–22
   PubMed Web of Science ®Google Scholar
• Lip GYH, Blann AD, Jones AF, et al. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764–71
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1: 459–61
   PubMed Web of Science ®Google Scholar
• Lindsay R, Tohme JF. Estrogen treatment in patients with established osteoporosis. Obstet Gynecol 1990; 76: 290–5
   PubMed Web of Science ®Google Scholar
• Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1990; 1: 7–13
   PubMedGoogle Scholar
• Michaëlsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-controlled study. Br Med J 1998; 316: 1858–63
   PubMed Web of Science ®Google Scholar
• Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. 1997; S3–S7, Osteoporos Int; Suppl. 1
   Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878–82
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256–61
   PubMed Web of Science ®Google Scholar
• Stracciari A, Guarino M, Ruozzi E, et al. An open trial on transdermal estrogen therapy in postmenopausal women with Alzheimer's disease. Alzheimer's Reports 1999; 2: 17–22
   Google Scholar
• Grodstein F, Stampfer MJ, Colditz G, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1992; 20: 47–63
   Google Scholar
• Olesen C, Steffense FH, Sorensen HT, et al. Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol 1999; 47: 323–8
   Google Scholar
• Erpecum KJ, van Berge Hengouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482–8
   Google Scholar
• Rovati LC. A new line of active-matrix transdermal systems for the management of ERT and HRT. Menopause Review 1998; 3(Suppl. 1)11–5
   Google Scholar
• Setnikar I, Rovati LC, Vens-Cappell B, et al. Bioavailability of estradiol from two transdermal patches. Arzneimittelforschung 1996; 46: 307–10
   PubMed Web of Science ®Google Scholar
• Rovati LC, Schmid K, Giacovelli G, et al. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies. Arzneimittelforschung 1999; 49: 933–43
   PubMed Web of Science ®Google Scholar
• FDA HRT Working Group. Guidance for clinical evaluation of combination estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women. Menopause 1995; 2: 131–6
   Web of Science ®Google Scholar
• Kupperman HS, Wetcler BB, Blatt MHG. Contemporary therapy of the menopause syndrome. J Am Med Assoc 1959; 171: 1627–37
   PubMed Web of Science ®Google Scholar
• de Aloysio D, Giacovelli G, Rovati LC, et al. Efficacy on climacteric symptoms and safety of low-dose estradiol transdermal matrix patches. A randomized, double-blind, placebo-controlled study. Arzneimittelforschung 2000; 50: 293–300
   PubMed Web of Science ®Google Scholar
• Pockock SJ. The size of a clinical trial. Clinical Trials: A Practical Approach, SJ Pocock. J. Wiley & Sons Ltd., ChichesterUK 1983; 123–41
   Google Scholar
• Hsu JC. Multiple Comparisons: Theory and Methods. Chapman and Hall Publ., London 1996
   Google Scholar
• Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Amer Statist Ass 1952; 47: 583–621
   Web of Science ®Google Scholar
• McNemar Q. Psychological Statistics 2nd edn. Wiley Publishing, New York 1955
   Google Scholar
• EC Guideline for Good Clinical Practice. Good Clinical Practice for Trials on Medicinal Products in the European Community. 1990, EEC document no III/3976/88-EN, approved by CPMP on 11/7/1990 and adopted by the Directive 91/507/CEE
   Google Scholar
• Setnikar I, Rovati LC, Vens-Cappell B, et al. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix. Arzneimittelforschung 1998; 48: 275–85
   Google Scholar
• Setnikar I, Rovati LC, Santoro A, et al. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch. Arzneimittelforschung 1999; 49: 708–15
   Google Scholar
• Setnikar I, Rovati LC, Thebault JJ, et al. Pharmacokinetic of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix. Arzneimittelforschung 1997; 47: 859–65
   Web of Science ®Google Scholar
• Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67–72
   PubMed Web of Science ®Google Scholar
• Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733–8
   PubMed Web of Science ®Google Scholar
• Reginster JY, Sarlet N, Deroisy R, et al. Minimum levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int 1992; 51: 340–3
   PubMed Web of Science ®Google Scholar
• Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6
   PubMed Web of Science ®Google Scholar
• Evans SF, Davis MW. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 1996; 44: 78–84
   Google Scholar
• Rozenbaum H. An overview of low-dose estrogen benefits. IV European Congress on Menopause, MH Birkhäuser, H Rozenbaum. Editions ESKA, Paris 1997; 183–95
   Google Scholar
• Rovati L, Rovati LC, Makovec F, et al. Transdermal Estradiol Delivery System. 1995, European Patent 0 614 356 B1, with priority 25.11.1991, 1995
   Google Scholar
• Utian WH. Transdermal estradiol overall profile. Am J Obstet Gynecol 1987; 156: 1335–8
   PubMed Web of Science ®Google Scholar